A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Oct 2021 Status changed from recruiting to discontinued (The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) isinferior to the expected, and this situation is very unlikely to be reversed if the trial isfully completed.)
- 05 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.